Brief: Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
01/03/2021 14:09
March 1 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS ANNOUNCES $25.4 MILLION REGISTERED
DIRECT
OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
* NABRIVA THERAPEUTICS -ENTERED INTO AGREEMENT WITH CERTAIN
INVESTORS FOR PURCHASE, SALE OF 10.4 MILLION ORDINARY SHARES(OR
PRE-FUNDED WARRANTS IN LIEU OF)
* NABRIVA THERAPEUTICS - ENTERED INTO AGREEMENT WITH CERTAIN
INVESTORS FOR PURCHASE, SALE OF WARRANTS TO PURCHASE UP TO 5.2
MILLION ORDINARY SHARES
* NABRIVA THERAPEUTICS PLC - EACH ORDINARY SHARE AND
ACCOMPANYING
WARRANT ARE BEING SOLD TOGETHER AT A COMBINED PURCHASE PRICE OF
$2.4525
Source text for Eikon: ID:nGNX7lcP7D
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update